Abstract 1451
Background
Avelumab is a human IgG1 monoclonal antibody against PD-L1, and axitinib is a potent inhibitor of VEGFR 1, 2, and 3. In a phase 3 study in patients (pts) with treatment-naive advanced renal cell carcinoma (aRCC; NCT02684006), avelumab in combination with axitinib (A+Ax) significantly improved progression-free survival (PFS) irrespective of PD-L1 expression vs sunitinib (S) at the preplanned interim analysis; median PFS was 13.8 mo with A+Ax vs 8.4 mo with S (HR, 0.69; p = 0.0001). Here, we report efficacy and safety in Japanese pts who were enrolled in this study.
Methods
Eligible pts with clear-cell aRCC, ECOG PS ≤ 1, and no prior systemic therapy were randomized 1:1 (stratified by ECOG PS and geographic region) to receive A 10 mg/kg IV Q2W + Ax 5 mg PO BID or S 50 mg PO QD on schedule 4/2. Primary endpoints were PFS by blinded independent central review (BICR) per RECIST v1.1 and overall survival (OS) in pts with PD-L1+ tumors (≥1% of immune cells). Key secondary endpoints were PFS by BICR and OS irrespective of PD-L1 expression. Other secondary endpoints included objective response rate (ORR), and safety.
Results
Japanese pts (N = 67) were randomized to A+Ax (n = 33) or S (n = 34); 67% vs 59% had PD-L1+ tumors; IMDC favorable/intermediate/poor risk status was 6%/64%/27% vs 6%/82%/12%. Median PFS (95% CI) was not estimable (NE) (8.1-NE) with A+Ax vs 11.2 months (1.6-NE) with S (HR, 0.49; 95%CI, 0.15-1.56) in pts with PD-L1+ tumors and 16.6 mo (8.1-NE) with A+Ax vs 11.2 mo (4.2-NE) with S (HR, 0.66; 95% CI, 0.30-1.46) in pts irrespective of PD-L1 expression. Median OS in either arm has not been reached in pts irrespective of PD-L1 expression. ORR (95% CI) was 60.6% (42.1%-77.1%) with A+Ax vs 17.6% (6.8%-34.5%) with S in pts irrespective of PD-L1 expression. Common treatment-emergent adverse events (all grade; grade ≥3) in each arm were hand-foot syndrome (64%; 9% vs 71%; 9%), hypertension (55%; 30% vs 44%; 18%), hypothyroidism (55%; 0% vs 24%; 0%), dysgeusia (21%; 0% vs 56%; 0%), and platelet count decreased (3%; 0% vs 65%; 32%).
Conclusions
A+Ax was efficacious and tolerable in Japanese pts with treatment-naive aRCC, which is consistent with results in the overall population.
Clinical trial identification
NCT02684006, Feb 17, 2016.
Editorial acknowledgement
Clinical Thinking, a Nucleus Global Company, Hamilton, NJ, USA.
Legal entity responsible for the study
Pfizer, Inc.
Funding
Funding for this study was provided by Pfizer, Inc. in alliance with Merck Healthcare KGaA, Darmstadt, Germany.
Disclosure
Y. Tomita: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Astellas; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono; Honoraria (self): Sanofi-Aventis; Honoraria (self): BMS; Advisory / Consultancy: Taiho; Advisory / Consultancy: MSD; Research grant / Funding (institution): Takeda. S. Hatakeyama: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Astellas; Honoraria (self), Research grant / Funding (institution): Kissei; Honoraria (self), Research grant / Funding (institution): Sanofi; Honoraria (self), Research grant / Funding (institution): Ono; Research grant / Funding (institution): Bristol; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Kaneka. H. Kanayama: Honoraria (self), Research grant / Funding (institution): Pfizer. K. Numakura: Honoraria (self): Pfizer; Honoraria (self): Astellas; Honoraria (self): Ono Pharm; Honoraria (self): Kyowa Kirin; Honoraria (self): AstraZeneca; Research grant / Funding (self): Grants-in-Aid for Scientific Research, the ministry of Education, Japan. T. Kato: Honoraria (self): Pfizer, Inc.; Honoraria (self): Novartis Pharma K.K; Honoraria (self): ONO Pharmaceutical Co., Ltd.; Honoraria (self): TAIHO Pharmaceutical Co., Ltd.; Honoraria (self): Chugai Pharmaceutical Co., Ltd.; Honoraria (self): Bayer Yakuhin, Ltd.; Honoraria (self): Astellas Pharma Inc. M. Eto: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Research grant / Funding (self): Bayer. H. Uemura: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono; Honoraria (self), Speaker Bureau / Expert testimony: BMS; Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self), Speaker Bureau / Expert testimony: MSD; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (self): Janssen; Advisory / Consultancy: Sanofi; Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Speaker Bureau / Expert testimony: Bayer; Research grant / Funding (self): Taiho; Research grant / Funding (self): Astellas; Research grant / Funding (self): Ono. R.J. Motzer: Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Inc.; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Incyte; Research grant / Funding (institution): Bristol-Myers Squibb (BMS); Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy: Merck. Y. Fujii: Full / Part-time employment: Pfizer R&D Japan. Y. Kamei: Full / Part-time employment: Pfizer R&D Japan. M. Oya: Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self), Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self): Ono; Honoraria (self): BMS. All other authors have declared no conflicts of interest.
Resources from the same session
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract
2152 - Inferring the correlation between incidence rates of melanoma and the average tumor-specific epitope binding ability of HLA class I molecules in different populations
Presenter: Istvan Miklos
Session: Poster Display session 3
Resources:
Abstract
4382 - Thermal Liquid Biopsy as a Valuable Tool in Lung Cancer Screening Programs
Presenter: Alberto Rodrigo
Session: Poster Display session 3
Resources:
Abstract
2465 - Towards a screening test for cancer by circulating DNA analysis
Presenter: Rita Tanos
Session: Poster Display session 3
Resources:
Abstract
3788 - Evaluation of a successful launch of the MammaPrint and BluePrint NGS kit
Presenter: Leonie Delahaye
Session: Poster Display session 3
Resources:
Abstract
3863 - Analysis of prognostic factors on overall survival in elderly women treated for early breast cancer using data mining and machine learning
Presenter: Pierre Heudel
Session: Poster Display session 3
Resources:
Abstract
1993 - Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα
Presenter: Na Li
Session: Poster Display session 3
Resources:
Abstract
4281 - CEUS of the breast: Is it feasible in improved performance of BI-RADS evaluation of critical breast lesions?——A multi-center prospective study in China
Presenter: Jun Luo
Session: Poster Display session 3
Resources:
Abstract
2268 - Classification of abnormal findings on ring-type dedicated breast PET for detecting breast cancer
Presenter: Shinsuke Sasada
Session: Poster Display session 3
Resources:
Abstract
4035 - Prediction of benign and malignant breast masses using digital mammograms texture features
Presenter: Cui Yanhua
Session: Poster Display session 3
Resources:
Abstract